Aurobindo Pharma Shares in Focus; API Facility Receives 2 USFDA Observations

Aurobindo Pharma’s Active Pharmaceutical Ingredients manufacturing facility in Telangana, inspected by the United States Food and Drug Administration between December 9 and December 17, 2024, received 2 procedural observations. The company plans to respond within the stipulated time.

Details of the Inspection

Aurobindo Pharma announced that the US FDA conducted an inspection of Unit-V, an API manufacturing facility of Apitoria Pharma Private Limited, a wholly owned subsidiary of the company.

The inspection took place at the facility located in Pashamylaram Village, Patancheru Mandal, Sanga Reddy District, Telangana, from December 9 to December 17, 2024.

At the conclusion of the inspection, the US FDA issued 2 observations, which are described as procedural in nature. The company emphasised that it would respond to these observations within the time frame stipulated by the US FDA.

Aurobindo Pharma has assured that it will keep the stock exchanges informed of any further developments related to this inspection.

Q2 FY25 Financial Highlights

Aurobindo Pharma reported an 8.6% year-on-year (YoY) increase in net profit, reaching ₹817 crore for the second quarter ending September 2024, against ₹752 crore in the same quarter of the previous year.

Revenue from operations grew by 8% YoY, amounting to ₹7,796 crore in Q2FY25. On a QoQ basis, revenue increased by 3%.

The company’s earnings before interest, tax, depreciation, and amortisation (EBITDA), excluding forex and other income, rose by 11.6% to ₹1,566 crore. As a result, the EBITDA margin for the quarter improved by 65 basis points YoY, reaching 20.1%.

Share Price Performance

On December 18, Aurobindo Pharma’s share price traded 2.88% higher at ₹1,248.65 by 11:55 AM on the NSE. The stock opened at ₹1,206.20, lower than ₹1,213.75 at the previous close.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.